These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 21511279)

  • 41. The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor beta-induced apoptosis.
    Yano T; Ito K; Fukamachi H; Chi XZ; Wee HJ; Inoue K; Ida H; Bouillet P; Strasser A; Bae SC; Ito Y
    Mol Cell Biol; 2006 Jun; 26(12):4474-88. PubMed ID: 16738314
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Frequent hemizygous deletion at 1p36 and hypermethylation downregulate RUNX3 expression in human lung cancer cell lines.
    Yanada M; Yaoi T; Shimada J; Sakakura C; Nishimura M; Ito K; Terauchi K; Nishiyama K; Itoh K; Fushiki S
    Oncol Rep; 2005 Oct; 14(4):817-22. PubMed ID: 16142337
    [TBL] [Abstract][Full Text] [Related]  

  • 43. RUNX3 methylation and the potential to predict the behavior of bladder cancer.
    Knapp DW
    J Urol; 2008 Sep; 180(3):806-7. PubMed ID: 18635238
    [No Abstract]   [Full Text] [Related]  

  • 44. RUNX3 is inactivated by promoter hypermethylation in malignant transformation of ovarian endometriosis.
    Guo C; Ren F; Wang D; Li Y; Liu K; Liu S; Chen P
    Oncol Rep; 2014 Dec; 32(6):2580-8. PubMed ID: 25333219
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epigenetic inactivation of the RUNX3 gene in lung cancer.
    Sato K; Tomizawa Y; Iijima H; Saito R; Ishizuka T; Nakajima T; Mori M
    Oncol Rep; 2006 Jan; 15(1):129-35. PubMed ID: 16328045
    [TBL] [Abstract][Full Text] [Related]  

  • 46. RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis.
    Ito K; Lim AC; Salto-Tellez M; Motoda L; Osato M; Chuang LS; Lee CW; Voon DC; Koo JK; Wang H; Fukamachi H; Ito Y
    Cancer Cell; 2008 Sep; 14(3):226-37. PubMed ID: 18772112
    [TBL] [Abstract][Full Text] [Related]  

  • 47. RUNX3 gene methylation in epithelial ovarian cancer tissues and ovarian cancer cell lines.
    Zhang S; Wei L; Zhang A; Zhang L; Yu H
    OMICS; 2009 Aug; 13(4):307-11. PubMed ID: 19645591
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of bladder tumour growth by histone deacetylase inhibitor.
    Ozawa A; Tanji N; Kikugawa T; Sasaki T; Yanagihara Y; Miura N; Yokoyama M
    BJU Int; 2010 Apr; 105(8):1181-6. PubMed ID: 19681894
    [TBL] [Abstract][Full Text] [Related]  

  • 49. RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor α.
    Huang B; Qu Z; Ong CW; Tsang YH; Xiao G; Shapiro D; Salto-Tellez M; Ito K; Ito Y; Chen LF
    Oncogene; 2012 Jan; 31(4):527-34. PubMed ID: 21706051
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest.
    Miyake M; Ishii M; Koyama N; Kawashima K; Kodama T; Anai S; Fujimoto K; Hirao Y; Sugano K
    J Pharmacol Exp Ther; 2010 Mar; 332(3):795-802. PubMed ID: 19955487
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers.
    Goel A; Arnold CN; Tassone P; Chang DK; Niedzwiecki D; Dowell JM; Wasserman L; Compton C; Mayer RJ; Bertagnolli MM; Boland CR
    Int J Cancer; 2004 Dec; 112(5):754-9. PubMed ID: 15386381
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Runt-related transcription factor 3 methylation as a possible prognosticator in muscle-invasive bladder cancer.
    Jeong P; Ha YS; Kim JS; Cho IC; Kim WT; Kim YJ; Yi Kim I; Yun SJ; Lee SC; Cha EJ; Kim WJ
    Cancer Biomark; 2011; 10(5):205-11. PubMed ID: 22699781
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin.
    Singh RP; Tyagi A; Sharma G; Mohan S; Agarwal R
    Clin Cancer Res; 2008 Jan; 14(1):300-8. PubMed ID: 18172282
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genetic variants in RUNX3 and risk of bladder cancer: a haplotype-based analysis.
    Zhang Z; Wang S; Wang M; Tong N; Fu G; Zhang Z
    Carcinogenesis; 2008 Oct; 29(10):1973-8. PubMed ID: 18684727
    [TBL] [Abstract][Full Text] [Related]  

  • 55. RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking.
    Wolff EM; Liang G; Cortez CC; Tsai YC; Castelao JE; Cortessis VK; Tsao-Wei DD; Groshen S; Jones PA
    Cancer Res; 2008 Aug; 68(15):6208-14. PubMed ID: 18676844
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of growth of mouse gastric cancer cells by Runx3, a novel tumor suppressor.
    Guo WH; Weng LQ; Ito K; Chen LF; Nakanishi H; Tatematsu M; Ito Y
    Oncogene; 2002 Nov; 21(54):8351-5. PubMed ID: 12447699
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer.
    Black PC; Brown GA; Dinney CP; Kassouf W; Inamoto T; Arora A; Gallagher D; Munsell MF; Bar-Eli M; McConkey DJ; Adam L
    J Urol; 2011 Feb; 185(2):693-700. PubMed ID: 21168861
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Emodin modulates epigenetic modifications and suppresses bladder carcinoma cell growth.
    Cha TL; Chuang MJ; Tang SH; Wu ST; Sun KH; Chen TT; Sun GH; Chang SY; Yu CP; Ho JY; Liu SY; Huang SM; Yu DS
    Mol Carcinog; 2015 Mar; 54(3):167-77. PubMed ID: 24115089
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Promoter methylation and expression of Runx3 gene in gastric cancer].
    Li LY; Li JK; Shen Y; Yu L; Zhang JH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jul; 11(4):379-82. PubMed ID: 18636364
    [TBL] [Abstract][Full Text] [Related]  

  • 60. RUNX3 promoter methylation in colorectal cancer: its relationship with microsatellite instability and its suitability as a novel serum tumor marker.
    Nishio M; Sakakura C; Nagata T; Komiyama S; Miyashita A; Hamada T; Kuryu Y; Ikoma H; Kubota T; Kimura A; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Kokuba Y; Sonoyama T; Ida H; Ito K; Chiba T; Ito Y; Otsuji E
    Anticancer Res; 2010 Jul; 30(7):2673-82. PubMed ID: 20682997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.